Table 3.

Relationship between expression of class III β-tubulin expression, response, progression on therapy, and survival in 47 NSCLC patients treated with a taxane-based regimen and 44 patients treated with a gemcitabine-based regimen

nResponse rate (%)PProgression rate (%)PProgression-free survival (d)POverall survival (d)P
Patients treated with taxanes
    <50% Class III2261.9<
    >50% Class III2512.5137.5105206
Patients treated with gemcitabine
    <50% Class III1733.3133.311650.763340.85
    >50% Class III2733.333.3140222.5